Ken Fisher’s Purple Biotech PPBT Stock Holding History

Ken Fisher’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-161	Closed	-$44K	–	1166
2022 Q4	$44K	Buy	+161	New	+$61.8K	﹤0.01%	1002

Other funds holding PPBT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VVP

Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return

WAOI

Wealth Advisors of Iowa West Des Moines, Iowa $369M AUM 18.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Ken Fisher's PPBT Position: Q1 2023 in Review

Ken Fisher sold out of Purple Biotech (PPBT) in Q1 2023, closing a stake of 161 shares — an estimated $44K sold.

Ken Fisher first reported a position in PPBT in Q4 2022 and held it in 1 quarter. The position peaked at $44K in Q4 2022. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2023.

Ken Fisher reported no remaining Purple Biotech position as of Q1 2023 after selling out during the quarter.
Ken Fisher sold 161 Purple Biotech shares in Q1 2023, an estimated $44K.
Ken Fisher first reported a position in Purple Biotech in Q4 2022 and held it in 1 quarter.
Ken Fisher's Purple Biotech position peaked at $44K in Q4 2022.
15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2023.

Based on Fisher Asset Management's 13F filing for Q1 2023, filed 1 May 2023.